Positive preclinical antiviral and safety profile of MIV-802 supports continued development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announce that the
preclinical antiviral and safety profile of MIV-802, Medivir’s wholly-owned
nucleotide polymerase inhibitor under development for the treatment of hepatitis
C virus (HCV) infection, was presented at The International Liver Congress™ 2015
of the European Association for the Study of the Liver (EASL), taking place in
Vienna from April 22-26.

The presentation, entitled “Preclinical characterization of MIV-802, a novel
uridine nucleotide HCV NS5B polymerase inhibitor, for treatment of hepatitis C
virus infection” (Abstract P0688), outlines the favourable preclinical profile
of MIV-802. This includes selective inhibition of the HCV NS5B polymerase by the
active metabolite of MIV-802 when compared with several human DNA and RNA
polymerases, the potent and selective pan-genotypic inhibition of HCV RNA
replication by MIV-802 in vitro, and its low toxicity in a range of in vitro and
in vivo studies. The presentation also describes preclinical studies that show
the selective delivery of high levels of the active metabolite of MIV-802 to the
liver. The data therefore support the continuing development of MIV-802 for the
future treatment of HCV infection in combination with other Direct Acting
Antivirals (DAAs).

Full session details and data presentation on www.medivir.com and listings for
The International Liver Congress™ 2015 can be found at http://www.ilc
-congress.eu.

For further information, please contact:
Ola Burmark, CFO Medivir AB, mobile: +46 (0)725-480 580.
Richard Bethell, EVP Research and Discovery, mobile: +46 (0)72-704 32 11

Medivir is required under the Securities Markets Act to make the information in
this press release public.
The information was submitted for publication at 14.00 CET on 23 April 2015.

About MIV-802
MIV-802 is a highly potent, pangenotypic nucleotide-based inhibitor of the HCV
NS5B polymerase, which recently entered preclinical development. Hepatitis C
treatment comprises a combination of several pharmaceuticals with different
mechanisms. Nucleotides are regarded as the most important component of any such
combination, due to their potent and broad spectrum antiviral effect on multiple
HCV genotypes and high barriers to the emergence of resistance. Preclinical data
indicate that MIV-802 can be used effectively in combination with other classes
of antiviral agents for the treatment of HCV, including protease inhibitors and
NS5A inhibitors.

About Medivir
Medivir is a research based pharmaceutical company with a research focus on
infectious diseases and oncology. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a growing portfolio of specialty care
pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm
Mid Cap List.